| Chen, Yu |
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer |
|
|
| Recruiting | 2 | 58 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 06/22 | 09/22 | | |
NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation |
|
|
| Recruiting | 2 | 30 | RoW | HLX208 | Shanghai Henlius Biotech | Advanced Melanoma | 08/23 | 08/24 | | |
NCT05823246: Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | QLF31907 | Qilu Pharmaceutical Co., Ltd. | Melanoma, Urothelial Carcinoma | 10/23 | 07/24 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT05664139: Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma |
|
|
| Not yet recruiting | 2 | 30 | NA | Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel | Fujian Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd., SunWay Biotech Co., LTD. | Malignant Melanoma, Liver Metastases | 12/24 | 12/25 | | |
NCT06081920: A Study of IBI363 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 2 | 120 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Melanoma | 06/25 | 07/26 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 1/2 | 42 | RoW | T3011 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Melanoma | 09/25 | 09/25 | | |
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 63 | RoW | SPH4336, Cadonilimab | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 05/25 | 12/25 | | |
| Recruiting | 1 | 189 | RoW | KY-0118 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Neoplasms, Neoplasms by Histologic Type | 12/25 | 12/25 | | |
NCT05989958: The Safety and Tolerability Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure |
|
|
| Recruiting | 1 | 12 | NA | HepaCure | Hexaell Biotech Co., Ltd. | Acute on Chronic Hepatic Failure, Liver Failure, Hepatitis | 09/24 | 09/24 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Recruiting | 1 | 144 | US, RoW | ADRX-0706 | Adcentrx Therapeutics | Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer | 09/25 | 12/26 | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
